Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208

Cancer Science

Volumn 99, Issue 1, 2008, Pages 145-151

  Tokuda, Yutaka ^a   Tajima, Tomoo ^a   Narabayashi, Masaru ^c   Takeyama, Kunihiko ^c   Watanabe, Toru ^c   Fukutomi, Takashi ^c   Chou, Takaaki ^d   Sano, Muneaki ^d   Igarashi, Tadahiko ^e   Sasaki, Yasutsuna ^e   Ogura, Michinori ^f   Miura, Shigeto ^f   Okamoto, Shin Ichiro ^g   Ogita, Masami ^h   Kasai, Masaharu ⁱ   Kobayashi, Tadashi ^j   Fukuda, Haruhiko ^k   Takashima, Shigemitsu ^b   Tobinai, Kensei ^c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NIIGATA CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ SAPPORO HOKUYU HOSPITAL   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NATIONAL CANCER CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; THIOTEPA;

EID: 36949036941     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00639.x     Document Type: Article

References (40)

1. Skipper HE. Dose intensity versus total dose chemotherapy: An experimental basis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA: Lippincott, 1990: 43-64.
2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
3. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J et al., for The Intergroupe Français du Myélome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-9.
4. Child JA, Morgan GJ, Davies FE et al., for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
5. Clarke M, Collins R, Darby S, Davies C et al., Early Breast Cancer Trialists'Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-717.
6. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-9.
7. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
8. Peters WP, Ross M, Vredenburgh J et al. High-dose alkylating agents and autologous bone marrow support (ABMS) for stage II/III breast cancer involving 10 or more axillary lymph nodes (Duke and CALGB 8782). Proc Am Soc Clin Oncol 1992; 11: 58a (Abstract).
9. Peters W, Berry D, Vredenburgh JJ et al. Five-year follow-up results of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving 10 axillary lymph nodes. Proc Am Soc Clin Oncol 1995; 14: 317 (Abstract).
10. Gianni A, Siena S, Bregni M et al. Five-year results of high-dose sequential adjuvant chemotherapy in breast cancer with 10 positive nodes. Proc Am Soc Clin Oncol 1995; 14: 90 (Abstract).
11. Bearman SI, Overmoyer BA, Bolwell BJ et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant 1997; 20: 931-7.
12. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7.years of follow-up. Ann Oncol 2002; 13: 689-98.
13. Hanrahan EO, Broglio K, Frye D et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. Follow-up at 12.years. Cancer 2006; 106: 2327-36.
14. Bergh J, Wiklund T, Erikstein B et al., for the Scandinavian Breast Group 9401 study. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Lancet 2000; 356: 1384-91.
15. Rodenhuis S, Bontenbal M, Beex LVAM et al., for the Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. New Engl J Med 2003; 349: 7-16.
16. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005; 23: 2191-200.
17. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). Proc Am Soc Clin Oncol 2001; 20: 21a (Abstract).
18. Roche H, Viens P, Biron P, Lotz J-P, Asselain B. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003; 10: 42-7.
19. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
20. Zander AR, Kröger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 2004; 22: 2273-83.
21. Leonard RCF, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer. J Natl Cancer Inst 2004; 96: 1076-83.
22. Nitz UA, Mohrmann S, Fischer J et al., for the West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 2005; 366: 1935-44.
23. Basser RL, O'Neill A, Martinelli G et al.: International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370-8.
24. Williams SF, Bitran JD, Kaminer L et al. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 1987; 5: 260-5.
25. Eder JP, Antman K, Elias A et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 1988; 80: 1221-6.
26. Kohno A, Takeyama K, Narabayashi M et al. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995; 15: 49-54.
27. Shimoyama M, Fukuda H, Saijo N, Yamaguchi N. Japan Clinical Oncology Group (JCOG). Jpn J Clin Oncol 1998; 28: 158-62.
28. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
29. Narabayashi M, Takeyama K, Fukutomi T et al. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Jpn J Clin Oncol 1999; 29: 285-90.
30. Tobinai K, Kohno A, Shimada Y et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250-7.
31. Tokuda Y, Tajima T, Narabayashi M et al. Randomized phase III study of high-dose chemotherapy with autologous stem cell support as consolidation in high-risk postoperative breast cancer. Japan Clinical Oncology Group (JCOG9208). Proc Am Soc Clin Oncol 2001; 20: 38a (Abstract).
32. Tormey DC, Weinberg VE, Holland JF et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1983; 1: 138-45.
33. Lichtman SM, Budman D, Bosworth J et al. Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. Am J Clin Oncol 1991; 14: 317-21.
34. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
35. Peto R. Update of worldwide evidence on the adjuvant treatment of breast cancer. Eur J Cancer 2002; 38 (Suppl 3): S22.
36. Rahman ZU, Frye DK, Buzdar AU et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-7.
37. Garcia-Carbonero R, Hidalgo M, Paz-Ares L et al. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 1997; 15: 3178-84.
38. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996; 14: 66-9.
39. Rodenhuis S, Bontenbal M, Van Hoesel QG et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 2006; 17: 588-96.
40. Nitz UA, Gluz O, Herr A et al. Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study. Proc Am Soc Clin Oncol 2006; 24: 44s (Abstract).